On March 5, 2024 Aprea Therapeutics, Inc. (Nasdaq: APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, reported four poster presentations at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, to take place April 5 to 10, 2024 in San Diego, CA (Press release, Aprea, MAR 5, 2024, View Source [SID1234640768]). The posters will cover ATRN-119, Aprea’s novel macrocyclic ATR inhibitor, and APR-1051, its next generation inhibitor of WEE1 kinase.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Title: First-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors harboring cancer-associated gene alterations
Presenter Nadeem Q. Mirza, MD, MPH
Session Title: First-in-Human Phase I Clinical Trials 2
Date and Time: Tuesday Apr 9, 9:00 AM – 12:30 PM PT
Location: Poster Section 48
Poster Board Number: 23
Abstract Presentation Number: CT195

Title: First-in-human phase 1/2a trial of a macrocyclic ATR inhibitor (ATRN-119) in patients with advanced solid tumors
Presenter Nadeem Q. Mirza, MD, MPH
Session Title: First-in-Human Phase I Clinical Trials 2
Date and Time: Tuesday Apr 9, 9:00 AM – 12:30 PM PT
Location: Poster Section 48
Poster Board Number: 24
Abstract Presentation Number: CT196

Title: The novel WEE1i, APR-1051, is a potentially well tolerated and effective treatment for cyclin E-overexpressing cancers
Presenter: Molly Hansbarger
Session Category: Experimental and Molecular Therapeutics
Session Title: DNA Damage and Repair Session
Date and Time: Wednesday Apr 10, 9:00 AM – 12:30 PM PT
Location: Poster Section 22
Poster Board Number: 16
Published Abstract Number: 7121

Title: Convection enhanced delivery of a novel ATR inhibitor synergizes with systemic lomustine for improved treatment of glioblastoma
Presenter: Teresa Lee, Ph.D
Session Category: Experimental and Molecular Therapeutics
Session Title: DNA Damage and Repair
Session Date and Time: Wednesday Apr 10, 9:00 AM – 12:30 PM PT
Location: Poster Section 22
Poster Board Number: 12
Published Abstract Number: 7117